Mark Scarupa, MD

A panelist discusses how each chronic spontaneous urticaria (CSU) therapy—omalizumab with its extensive safety record, oral remibrutinib for omalizumab nonresponders, and potent barselolizumab for treatment-resistant cases—offers unique benefits and limitations, emphasizing the importance of shared decision-making and patient education to dispel misconceptions and tailor care.

A panelist discusses long-term omalizumab studies showing symptom relapse after discontinuation, contrasting this with barselolizumab data where over a third of patients remained symptom free months after stopping treatment, suggesting potential for sustained remission and disease modification in chronic spontaneous urticaria (CSU).

A panelist discusses the promising potential of anti-KIT therapies, especially barselolizumab, in chronic spontaneous urticaria (CSU) treatment, and highlights their superior efficacy, possible disease-modifying effects, and the potential to improve quality of life for a broader range of patients compared with existing options.

A panelist discusses the potential of remibrutinib as an effective oral alternative to omalizumab for chronic spontaneous urticaria (CSU), noting its rapid onset, promising trial results, and anticipated use in patients who prefer oral therapy or have not responded to biologics.

A panelist discusses the limited role of dupilumab in omalizumab-refractory chronic spontaneous urticaria (CSU), noting variation in its use across specialties and highlighting ongoing unmet needs for more diverse, effective treatment options—including oral agents and longer-acting injectables—to support individualized care.

A panelist discusses how the current goal in managing chronic spontaneous urticaria (CSU) is complete symptom control, balanced with patient preferences, while highlighting the future promise of disease-modifying therapies that could shorten disease duration and shift care from long-term suppression to potential remission.

A panelist discusses how the unpredictable and often distressing symptoms of chronic spontaneous urticaria (CSU) can severely impact patients’ quality of life, emphasizing the emotional burden, misinformation about triggers, and the importance of tracking both symptom control and well-being through validated outcome measures.

A panelist discusses how chronic spontaneous urticaria (CSU), which makes up approximately 80% of chronic urticaria cases, is distinguished by fleeting hives and often angioedema, frequently linked to autoimmune thyroid disease, and highlights the importance of early recognition and referral to specialists for timely diagnosis and management.